Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010 Oct; 20(7):1125-31.
View in:
PubMed
subject areas
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Carboplatin
Chemotherapy, Adjuvant
Chemotherapy, Adjuvant
Cystadenocarcinoma, Serous
Cystadenocarcinoma, Serous
Drug Administration Schedule
Drug Administration Schedule
Female
Female
Humans
Humans
Middle Aged
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm Staging
Ovarian Neoplasms
Ovarian Neoplasms
Paclitaxel
Paclitaxel
Retrospective Studies
Retrospective Studies
Risk Factors
Risk Factors
Survival Rate
Survival Rate
Treatment Outcome
Treatment Outcome
authors with profiles
Debra L Richardson